Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Alisertib: Development discontinued

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Alisertib (MLN8237) Business: Cancer Molecular target: Aurora kinase A (AURKA) (Aurora-A) Description: Second-generation Aurora kinase A (AURKA; Aurora-…

    Published on 5/18/2015
  • APD403: Phase II data

    Acacia Pharma Ltd., Cambridge, U.K. Product: APD403 Business: Gastrointestinal Molecular target: Dopamine D2 receptor; Dopamine D3 receptor (DRD3) Description: IV formulation of amisulpride, an off-patent dopamine D2 …

    Published on 5/18/2015
  • Clazakizumab: Phase IIb data

    Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Bothell, Wash. Product: Clazakizumab (formerly ALD518, BMS-945429) Business: Autoimmune Molecular target: Interleukin-6 (IL-6) Description: Humanized mAb against IL-6 …

    Published on 5/18/2015
  • Contrave naltrexone SR/bupropion SR: Phase III discontinued

    Orexigen Therapeutics Inc. (NASDAQ:OREX), La Jolla, Calif. Product: Contrave naltrexone SR/bupropion SR (Mysimba - EU) (NB32) Business: Endocrine/Metabolic Molecular target: Mu opioid receptor (MOR) (OPRM1) Description:…

    Published on 5/18/2015
  • Daklinza daclatasvir: Interim Phase II data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Daklinza daclatasvir (BMS-790052) Business: Infectious Molecular target: HCV NS5A protein Description: Selective HCV NS5A protein inhibitor Indication: Treat …

    Published on 5/18/2015
  • Dalazatide: Phase Ib data

    Airmid Inc., Redwood City, Calif. Kineta Inc., Seattle, Wash. Product: Dalazatide (formerly ShK-186) Business: Autoimmune Molecular target: Potassium channel Kv1.3 (KCNA3) Description: Synthetic peptide that inhibits …

    Published on 5/18/2015
  • Demcizumab: Additional Phase Ib data

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Demcizumab (OMP-21M18) Business: Cancer Molecular target: Delta-like 4 (DLL4) Description: Humanized IgG2 mAb against delta-like 4 (DLL4) …

    Published on 5/18/2015
  • Epi proColon: Clinical trial data

    BioChain Institute Inc., Newark, Calif. Epigenomics AG (Xetra:ECX; OTCQX:EPGNY), Berlin, Germany Product: Epi proColon, Epi proColon 2.0 Business: Diagnostic Molecular target: Septin 9 (SEPT9) Description: Second-…

    Published on 5/18/2015
  • EpiFix: Clinical trial data

    MiMedx Group Inc. (NASDAQ:MDXG), Marietta, Ga. Product: EpiFix Business: Dermatology Molecular target: NA Description: Human amniotic allograft Indication: Treat diabetic foot ulcers Endpoint: Percentage of wounds …

    Published on 5/18/2015
  • Humira adalimumab: Phase III data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Humira adalimumab Business: Ophthalmic Molecular target: Tumor necrosis factor (TNF) alpha Description: Human mAb against tumor …

    Published on 5/18/2015
  • Imvamune: Phase II data

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Product: Imvamune (Imvanex) Business: Infectious Molecular target: Not applicable Description: Third-generation modified vaccinia Ankara (MVA) virus vaccine Indication…

    Published on 5/18/2015
  • Imvamune: Phase III data

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Product: Imvamune (Imvanex) Business: Infectious Molecular target: Not applicable Description: Third-generation modified vaccinia Ankara (MVA) virus vaccine Indication…

    Published on 5/18/2015
  • Latuda lurasidone: Updated Phase III data

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Latuda lurasidone (SM-13496) Business: Neurology Molecular target: Dopamine D2 receptor; …

    Published on 5/18/2015
  • LY2606368: Phase I data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY2606368 Business: Cancer Molecular target: Checkpoint kinase 1 (Chk1) (CHEK1) Description: Checkpoint kinase 1 (Chk1; CHEK1) inhibitor Indication: Treat …

    Published on 5/18/2015
  • MSPrecise Blood Assay: Pivotal trial preliminary data

    Amarantus BioScience Holdings Inc. (OTCQB:AMBS), San Francisco, Calif. Product: MSPrecise Blood Assay Business: Diagnostic Molecular target: NA Description: Next-generation DNA sequencing assay that measures mutations …

    Published on 5/18/2015
  • Olysio simeprevir: Interim Phase II data

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Olysio simeprevir (Sovriad, Galexos) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 5/18/2015
  • Opdivo nivolumab: Additional Phase Ib data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 5/18/2015
  • Opdivo nivolumab: Additional Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 5/18/2015
  • Opdivo nivolumab: Interim Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 5/18/2015
  • Prostate cancer liquid biopsy test: Clinical trial data

    Exosome Diagnostics Inc., Cambridge, Mass. Product: Prostate cancer liquid biopsy test Business: Diagnostic Molecular target: NA Description: Non-invasive, urine-based liquid biopsy prostate cancer test that analyzes …

    Published on 5/18/2015
  • PT20: Phase IIb data

    Phosphate Therapeutics Ltd., Newcastle, U.K. Product: PT20 Business: Endocrine/Metabolic Molecular target: NA Description: Iron-based phosphate binder Indication: Treat hyperphosphatemia Endpoint: Serum phosphate; …

    Published on 5/18/2015
  • RBP-7000: Phase III data

    Indivior plc (LSE:INDV), Richmond, Va. Product: RBP-7000 Business: Neurology Molecular target: NA Description: Once-monthly sustained-release formulation of risperidone using the Atrigel delivery system Indication: …

    Published on 5/18/2015
  • Remogliflozin etabonate: Additional Phase IIb data

    BHV Pharma Inc., Research Triangle Park, N.C. Islet Sciences Inc. (OTCBB:ISLT), New York, N.Y. Kissei Pharmaceutical Co. Ltd. (Tokyo:4547), Nagano, Japan Product: Remogliflozin etabonate (BHV091009, KGT-1681) (formerly …

    Published on 5/18/2015
  • Remoxy oxycodone: Clinical trial data

    Durect Corp. (NASDAQ:DRRX), Cupertino, Calif. Pain Therapeutics Inc. (NASDAQ:PTIE), Austin, Texas Product: Remoxy oxycodone (PF-00345439) Business: Neurology Molecular target: Mu opioid receptor (MOR) (OPRM1); Kappa …

    Published on 5/18/2015
  • Sovaldi sofosbuvir: Interim Phase II data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Sovaldi sofosbuvir (GS-7977) (formerly PSI-7977) Business: Infectious Molecular target: HCV NS5B polymerase Description: Nucleotide analog HCV NS5B …

    Published on 5/18/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993